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Abstract
Hypoxia inducible factor and nuclear factor-kappa beta pathways have been proposed as therapeutic targets for several inflam-
matory diseases. Caffeic acid phenethyl ester (CAPE) and piceatannol (PIC) are natural anti-inflammatory compounds; however,
poor bioavailability and limited understanding of biomolecular mechanistic limits its clinical use. The aims of this study are to
enhance bioavailability and investigate their impact on nuclear p65 and HIF-1α for the first time in experimental colitis.
Dextran sulphate sodium was used to induce colitis in mice and effect of either free CAPE/PIC or CAPE/PIC loaded albumin
nanoparticles treatment was observed on disease development and levels of cellular p65 and HIF-1α.
Our results indicate that albumin nano-encapsulation of CAPE/PIC not only enhances its anti-inflammatory potential but also
potentiates its ability to effectively modulate inflammation related biomolecular pathways. Hence, combining nanotechnology
with natural compounds could result in development of new therapeutic options for IBD.
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Background
Inflammation of the gastrointestinal tract is in fact a pro-
tective mechanism via which the host tries to protect itself
from invading pathogens and noxious stimuli. The prima-
ry purpose of the inflammatory response is to remove and
or inactivate the harmful substance; this process is sup-
ported by an array of cell-derived proteases and reactive
oxygen products , as well as soluble mediators .
Inflammation is normally self-limiting. However, in some
cases, inflammation can become chronic leading to
development of inflammatory bowel disease (IBD), a term
commonly used to describe both ulcerative colitis (UC)
and Crohn’s disease (CD). These gastrointestinal disor-
ders have no effective treatment [1–3] and share common
symptoms, such as weight loss, diarrhoea, rectal bleeding
and abdominal cramp [4]. However, both disorders differ
in affected location, with UC prevalent in the large intes-
tine [5] and CD being of more variable occurrence in the
gastrointestinal tract [6]. Both diseases present cryptic ab-
scess, cryptitis and alteration in the mucosal layer [6]. The
exact aetiology of IBD is unclear, but aberrant immunity,
environmental factors, genetic disorders and dysregulation
of the mucosal layer are thought to be responsible for the
colitis [7]. These factors produce mucosal hypoxia and
cause over activation of hypoxia-inducible factor 1
(HIF-1α) and nuclear factor-kappa beta (NF-kβ) [8, 9].
As a consequence, elevated levels of both transcription
factors are frequently documented in colitis of the human
colon [10].
UC occurs more frequently than Crohn’s disease [11] and
damage to the mucosal layer is thought to be the main cause
[12, 13]. The healthcare cost associated with management is
considerable, especially in the USA, Europe and Asian coun-
tries [14–18]. The predominant drug-based therapies used in
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UCmanagement, such as aminosalicylic acid, corticosteroids,
6-mercaptopurine, azathioprine and cyclosporine give rise to a
range of debilitating side effects at various sites, such as skin,
eyes andmuscle [19, 20]. These therapeutic agents also induce
bone marrow depletion and disorders in the lungs, liver and
pancreas [21–23]. Additionally, these treatments are not only
non-selective, but also impair lifestyle due to repeated use for
protracted periods of time [24, 25]. Hence, simple drug-based
interventions are of limited effectiveness in treating UC, lead-
ing inevitably to more series outcomes. These include elective
procedures used to prevent further complications, such as co-
lorectal cancer [26]. More sophisticated approaches based on
novel and potent therapeutic agents, such as monoclonal anti-
bodies, protease inhibitors and anti-TNF-α compounds, are
also used in UC [27, 28] but their use has limitations due to
side effects linked to liver damage, heart disease, infection,
skin disease and degenerative disorders [25]. Arguably, the
use of biomolecular drug substances offer few advantages,
yet inflict toxicity, non-selectivity and a cost burden on pa-
tients [21].
There is a current and pressing need for alternative drug-
based therapies to treat UC, which provide better healing,
increase specificity and lower toxicity profiles, together with
improved cost and convenience to patients. Compounds of
natural origin, such as curcumin, caffeic acid phenethyl ester
(CAPE) and piceatannol (PIC) could be used as adjutants to
current clinically used anti-inflammatory, immune-
suppressants and biologicals to improve therapeutic outcome,
in the near future [22, 29]. PIC is naturally occurring agent
present in grapes, red wine and passion fruit [30] and CAPE is
derived from honeybee hives [31]. Together, they possess an-
tioxidant properties and stabilise free radicals. They control
inflammation and inhibit over stimulation of NF-kB and HIF-
1α [32, 33]. They modulate overexpress of NF-kB by
inhibiting pro-inflammatory mediators in colitis [34, 35] and
prevent the binding of NF-kβ with DNA or inhibition of Ikβ
in the cytoplasm [36, 37].
Although PIC and CAPE possess no known side effects
and have beneficial activity that could be used to treat IBD,
these compounds possess low solubility and poor bioavail-
ability that limit their efficacy [38, 39]. Therefore, an aim of
this work is to use nano-encapsulation to improve PIC and
CAPE. The matrix selected was albumin, which is widely
used as a biocompatible carrier that stabilises plasma pH, al-
leviates osmotic pressure and had been used to deliver pro-
teins to cells [40]. Albumin nanoparticles (NP) have been
shown to taken by cells due to inflammation at the mucosal
site [41, 42]. Additionally, albumin is known to aggregate at
sites of inflammation and tumour due to its affinity towards
neutrophils, hence albumin nanoparticles could be used to
target inflamed colon tissue in colitis [43].
There have been no previous published reports of al-
bumin NP, loaded with PIC and CAPE, being evaluated in
a murine model of chemically induced colitis. Our previ-
ous work has shown that CAPE is protective in experi-
mental colitis at a dose of 30 mg kg−1 day−1 and was
found ineffective at any lower doses [23]. Hence, in the
present work, we have evaluated the effect of albumin NP
loaded with PIC and CAPE at 20 mg kg−1 day−1 in a
mouse (C57BL/6) model of DSS-induced colitis. The
DSS model of colitis has been the first choice for colitis
research since it is a simple model which produces robust
results, however it lacks the immunological element of the
disease; despite this shortcoming, it is known to produce
an inflammatory response which is pathologically similar
to human colitis [44].
The overarching aim of this study is to understand the
dynamics of hypoxia inducible factor (HIF) and nuclear
factor-kappa beta (NF-kβ) during active inflammation.
Since, PIC and CAPE have limited solubility in aqueous me-
dia, we used a desolvation method to formulate albumin NP,
loaded with PIC and CAPE to improve the solubility of these
compounds. We have performed immuno-histochemistry and
ELISA assays on colon tissue samples to quantify the activity
of HIF-1a and nuclear p65 during active inflammation in ex-
perimental colitis.
Methods
Materials
Piceatannol (cat no.: P1928, purity > 98%, CAS: 10083-
24-6) was obtained from Tokyo Chemical Industry UK
Ltd., Oxford, UK. Caffeic acid phenethyl ester (cat no.:
C8221, purity > 97%), albumin from bovine serum (cat
no.: A2153, lot no.: 049k1585) and glutaraldehyde so-
lution (cat no.: G5882) were obtained from Sigma
Aldrich Ltd., Poole, UK. Dextran sodium sulphate
(DSS) (cat no.: 160110, lot no.: M2356, molecular
weight: 36000–50,000) was obtained from Fisher
Scientific Ltd., Leicester, UK. Primary and secondary
antibodies were purchased from Abcam, UK. All sol-
vents used in the study were of HPLC grade and re-
agents were of analytical grade or higher. Ultrapure wa-
ter was of type 1 standard (ISO 3696, Milli-Q®) and
used throughout the study.
Preparation of PIC/CAPE-loaded albumin
nanoparticles
Albumin NP were loaded with either PIC or CAPE and
fabricated using a desolvation method, with slight modi-
fication [45]. Briefly, CAPE/PIC (10 mg, 20 mg or
30 mg) was dissolved in ethanol (8.0 ml) and added to a
2% w/v BSA solution (2.0 ml) dropwise under constant
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stirring, leading to coacervate formation. An identical pro-
cedure using 10 mg, 20 mg or 30 mg of CAPE/PIC was
used to prepare PIC-loaded NP. Coacervates were cross-
linked using 8.0% w/v glutaraldehyde (100 μl) and stirred
overnight at 500 rpm to remove traces of organic solvent.
NP were collected by centrifugation (10,000×g) at 4 °C
Fig. 1 Effect of PIC loading on
particle size, polydispersity index
(PDI), zeta potential and
entrapment efficiency. Increases
in PIC concentration significantly
(p < 0.01) increase the particle
size (a), PDI (b) and (p < 0.001)
zeta potential (c). Entrapment
efficiency decreases significantly
(p < 0.01) due to increase in PIC
amount. Values are mean ± SEM
(n = 3). *p < 0.05, **p < 0.01 and
***p < 0.001
Fig. 2 Effect of increase in CAPE
concentration on particle size,
polydispersity index (PDI), zeta
potential and entrapment
efficiency. Increases in CAPE
concentration results in small (ns)
increase the particle size (a) and
PDI (b). However, zeta potential
(c) increases significantly
(p < 0.01) as CAPE amount
increases. Entrapment efficiency
(d) decreases significantly
(p < 0.01) due to increase in
CAPE amount. Values are mean ±
SEM (n = 3). **p < 0.01
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and washed three times with ultra-purified water. After
washing, the albumin NP pellet was frozen at − 20 °C
for 6 h and lyophilised (4.5 Plus, Labconco Ltd., USA)
for 48 h.
Albumin NP characterisation
Particles size and zeta potential
The particle size and distribution of PIC/CAPE-loaded albu-
min NP were measured using dynamic light scattering
(Zetasizer 5000, Malvern Instruments, Malvern, UK). An al-
iquot of NP suspension (5 mg/ml) (1:5 dilution), previously
vortex mixed, was diluted with ultrapure water and used to
measure mean size and polydispersity index. Electrophoretic
mobility was used to evaluate the zeta potential of PIC/CAPE-
loaded albumin NP. Conductivity was adjusted using 0.001 M
KCl. The average of three measurements was documented.
Entrapment efficiency
Entrapment efficiency was calculated using an indirect meth-
od. The concentration of non-encapsulated PIC/CAPE in the
supernatant were measured by absorption spectrophotometry
(CAPE at 425 nm/PIC at 325 nm) and compared to a standard
plot. The amount of entrapped PIC/CAPE inside the NP was
measured from the difference between the initial amount of
PIC/CAPE added and the non-encapsulated PIC/CAPE re-
maining in the external aqueous phase after NP formulation.
All measurements were recorded in triplicate and the average
of each sample was expressed as the percentage of PIC/CAPE
entrapment efficiency.
Administration of PIC and CAPE-loaded albumin NP
in mice
Five/six mice were assigned to groups, comprising healthy
control, DSS control, free drug (PIC or CAPE) with DSS
and PIC or CAPE-loaded albumin NP with DSS.
Intraperitoneal injection of 20 mg/kg of free drug (PIC or
CAPE) and equivalent amount (PIC or CAPE) of NP was
administered in sterile PBS to mice.
Induction of colitis and colon assessment
All animal procedures described in this work were approved by
the Ulster University Animal Research Ethics Committee and
UK Home Office, under project licence (PL2768). Colitis was
induced in 12-week-old C57BL/six female mice (Charles River
Ltd., Canterbury, UK) by administering 2.5% w/v DSS in drink-
ing water over a period of 6 days. The disease activity index
(DAI) score was used to record morphological changes, such
as weight loss, stool consistency and presence of blood in the
faeces. Upon termination of the experiment, mice were sacrificed
Fig. 3 Effect of PIC and CAPE-
loaded albumin NP treatment on
percentage weight change and
disease activity index (DAI). PIC
(a and c) and CAPE (b and d)-
loaded albumin nanoparticle
treated group shows lower weight
loss and low DAI as compared to
the free PIC and CAPE-treated
mice. N = 5–6 mice per group.
*p < 0.05 and ***p < 0.001
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by cervical dislocation [46]. The isolated colon was excised,
washed in PBS and laid flat on moist tissue paper to measure
its length. After removing the colonic content from each colon,
its weight was measured to assess the change in colon weight.
Approximately 1.0 cm of excised colonic tissue were fixed in
10% paraformaldehyde (pH 7.4; phosphate-buffered saline) and
embedded in paraffin. Sections (4 μm) were cut and stained with
haematoxylin and eosin. Histological assessment and scoring of
colon tissue sections were carried out in a blinded fashion based
on defined parameters, such as stool frequency, rectal bleeding,
mucosal appearance and disease activity rating [47]. All tissue
slides were imaged using optical microscope (AxioCam MRc
ZEISS) light microscopy.
Colon myeloperoxidases and cytokine measurements
The colonic tissue lysate was blended and homogenised as
described by [23]. The expression of pro-inflammatory cyto-
kines INF-γ, IL-6 and TNF-α, were quantified using V-Plex
Assay Plates (Meso Scale Diagnostics; Rockville, MD, USA)
and analyse as per the manufacturer’s. MPO activity was de-
tected using o-phenylenediamine dihydrochloride as substrate
and the data were interpolated from an MPO standard curve
(Sigma). Expression of cytokines and MPO was represented
as per milligram or U per milligram, respectively, relative to
colonic protein.
Immunohistochemistry
Colon tissues were stored in formalin and embedded in paraffin.
Sections (5 μm) were mounted on glass slides (Superfrost
Plus®), washed twice in xylene (10 min each) and rehydrated
in decreasing concentration of ethanol for 5 min. It was then
submerged in a glass jar filled with sodium citrate buffer (pH
6) kept in water bath at 95 °C, for 20 min. After heating for
20 min, the glass jar was removed from the water bath and
allowed to cool at room temperature for 20 min. The slide was
then washed in PBS twice for 5 min and blocking performed in
5% w/v BSA solution for 1 h at room temperature. Slides were
washed twice again for 5 min and then incubated with secondary
antibody for 1 h at room temperature. The tissue sectionwas then
stained with DAPI for 15 min and antifade was applied and
sealed with coverslip. The sectioned was observed under an op-
tical microscope (AxioCam MRc ZEISS) [48].
Quantification of p65 and HIF-1α levels
The colonic tissue lysate from healthy, DSS, free drug of PIC or
CAPE and PIC or CAPE-loaded albumin NP-treated mice were
prepared and levels of p65 and HIF-1α were analysed using
Invitrogen NF-kβ p65 (total) Human ELISA Kit (KHO0371)
and HIF-1α Human ELISA Kit (EHIF1A) as per manufactures
protocol at 450 nm using a BioTek optical plate reader. Optical
density was converted to concentration (pg/ml) using the standard
calibration curve provided in the manufactures protocol [49].
Statistical analysis
Results were expressed as mean ± standard error of the mean
(SEM) for a series of experiments. Data were assumed to be
normally distributed and statistical analyses were carried out
using Prizm GraphPad V6 software (GraphPad, San Diego,
CA, USA). A paired t test was used for comparisons of paired
treatments between two groups, unpaired t tests for compari-
sons of unpaired treatments between two groups and one-way
ANOVA using Bonferroni multiple comparisons tests for
treatments of three groups or more. p values ≤ 0.05 were con-
sidered to be significant [23].
Results
Optimisation of PIC and CAPE-loaded albumin NP
The effect of drug content was studied on particle size, poly-
dispersity index and zeta potential. Drug-loaded albumin NP
were formulated with 10 mg, 20 mg and 30 mg of free drug.
An increase in particle size (210 to 288 nm) was observed
when PIC amount increases from 10 to 30 mg (Fig. 1a).
This increase in particle size may be due to increase amount
of drug which in turn increases the viscosity of drug solution.
Polydispersity index significantly (p < 0.01) increases (0.11 to
0.18) as drug amount increases (Fig. 1b). Likewise, zeta po-
tential significantly (p < 0.001) increases (− 20 to − 8 mV)
with increased PIC amount in the formulation (Fig. 1c).
Additionally, entrapment efficiency significantly decreases
(60 to 38%) due to increase in PIC concentration (Fig. 1d).
However, increase in CAPE amount does not show any sig-
nificant effect on particle size and polydispersity index as
depicted in Fig. 2a, b. Although, significant (p < 0.01) in-
crease in zeta potential (− 15 to − 9 mV) and decrease in en-
trapment efficiency (56 to 45%) was observed as illustrated in
Fig. 2c, d.
PIC and CAPE-loaded albumin NP alleviate weight loss
and improves DAI in DSS-induced colitis
Mice were assigned to six groups, comprising healthy control,
DSS 2.5% w/v alone, free drug (PIC/CAPE) along with DSS
2.5% w/v and PIC/CAPE-loaded albumin NP with DSS 2.5%
w/v. Intraperitoneal injection of 20 mg/kg of free drug (PIC/
CAPE) and equivalent amount of albumin NP containing
CAPE/PIC was administered in sterile PBS to the mice.
Change in weight was monitored daily and symptoms of co-
litis such as diarrhoea, weight loss and blood in faeces were
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reported as composite score of DAI. Post-mortem colon
weight and length were noted on the final day [44, 50].
Comparative protective activity of NP (PIC/CAPE) and
free drugs (PIC/CAPE) was studied on C57BL/6 mice for
6 days. Documentation of weight of each mouse in all group
were carried out daily. PIC/CAPE-loaded albumin NP + DSS
group reported significantly (p < 0.001) less weight loss as
compared to free PIC + DSS, free CAPE + DSS and DSS
alone groups (Fig. 3a, b.
Furthermore, PIC/CAPE-loaded albumin NP + DSS group
exhibit significant (p < 0.05) lower DAI score as compared to
free PIC + DSS, free CAPE + DSS and DSS alone groups
Fig. 3c, d.
The above finding suggests that PIC/CAPE-loaded albumin
NP can significantly attenuate the inflammatory symptoms in
experimental colitis such as diarrhoea, weight loss and blood in
faeces as compared with free PIC/CAPE, indicating that albumin
NP-based drug delivery can improve the therapeutic outcome.
Colon morphology is improved after treatment
with PIC/CAPE-loaded albumin NP in experimental
colitis
Shortening of colon length and alteration in colon morphology
is other characteristics of human colitis andDSS-induced colitis
in mice [51]. In our current study, effect of free drugs (PIC/
CAPE) and albuminNP containing PIC/CAPE on post-mortem
colon length and weight was recorded (Fig. 4). The stool in the
healthy group appeared to be normal (Fig. 4 A first picture).
Loose stool with a blood clot is seen in the colon of mice treated
with DSS only and free PIC/CAPE along with DSS, (Fig. 4a).
PIC-loaded albumin NP (Fig. 4a, picture 4) and CAPE-loaded
albumin NP (Fig. 4a, picture 4) shows no sign of blood clots
during experimental colitis. Well-formed stool pellets can be
seen in CAPE-loaded albumin NP (Fig. 4a, picture 4).
PIC/CAPE-loaded albumin NP illustrates significant
(p < 0.01/p < 0.05) higher colon length than DSS alone and
free PIC/CAPE groups (Fig. 4b). Treatment of PIC-loaded
albumin NP (p < 0.05) and CAPE-loaded albumin NP
(p < 0.05) in mice protects the loss in colon weight (Fig. 4c)
as compared to free PIC and CAPE and DSS alone groups.
Therefore, above data suggest that PIC/CAPE-loaded albumin
NP improves the overall morphology of the colon during ac-
tive colitis in a murine model of DSS-induced colitis.
Histological investigation in mice treated
with PIC/CAPE-loaded albumin NP
Histological investigation of colonic epithelia treated with
DSS demonstrated an alteration in structural integrity along
Fig. 4 Effect of PIC and CAPE-
loaded albumin NP treatment on
colon morphology, length and
weight. PIC/CAPE-loaded
albumin NP + DSS treatment is
effective in protecting gross
anatomy and colon length as
compared to the DSS group and
free PIC/CAPE treatment. Gross
appearance of the colonic
anatomy shows the effect of PIC
and CAPE-loaded albumin NP +
DSS, free PIC and CAPE and
DSS alone groups on colon
shortening and formation of
faecal pellets (a). The colon of
mice treated with PIC
nanoparticles closely resembles
colon of the healthy group.
However, free PIC shows loose
stool, blood in faeces and shorter
colon length same as the DSS
treated group. Similarly, colon
length and weight of PIC/CAPE-
loaded albuminNP treatedmice is
not adversely effected (b and c).
N = 5–6mice per group. *p < 0.05
and ***p < 0.001, Δp < 0.05 and
ΔΔp < 0.01
Drug Deliv. and Transl. Res.
with permeation of inflammatory neutrophils inside the
distorted epithelial layer in mouse colon of DSS alone and
free PIC/CAPE-treated groups (Fig. 5a). However, the degree
of cryptic epithelial damage and infiltration of inflammatory
cells is very low in PIC/CAPE-loaded albumin NP-treated
mice as compared to free PIC/CAPE and DSS groups
(Fig. 5a). Blinded tissue inflammation scores of colonic tis-
sues histology indicates significant (p < 0.001) reduction of
inflammation score (composite score of crypt damage and
inflammation) in PIC/CAPE-loaded albumin NP-treated mice
relative to DSS control and free PIC/CAPE-treated mice
(Fig. 5b).
Colon myeloperoxidases and cytokine measurements
We further examined the expression of colonic inflammatory
markers in mice colon tissue when exposed to DSS and being
treated with free PIC/CAPE and albumin-loaded PIC/CAPE.
DSS alone control mice showed a significant increase inMPO
levels, a marker for inflammation and leukocyte infiltration
(Fig. 6a). There was attenuation of MPO expression in mice
treated with free PIC/CAPE; however, mice treated with PIC/
CAPE-loaded albumin NP reported significant (p < 0.01)
reduction of MPO as compared to DSS alone and free PIC/
CAPE groups (Fig. 6a). Similarly, the level of inflammatory
markers such as INF-γ, IL-6 and TNF-α decreases signifi-
cantly (p < 0.01) in PIC/CAPE-loaded albumin NP-treated
groups as compared with DSS alone and free PIC/CAPE
groups (Fig. 6b–d).
Level of p65 and HIF-1α in PIC and CAPE-loaded
albumin NP tissue
Expression of HIF and NF-kβ transcription proteins namely
HIF-1α and p65 was observed in mouse colon tissue using
fluorescence immunohistochemistry. Noticeable decrease in
the expression of HIF-1α and p65 was observed in colonic
tissue of mice treated with PIC/CAPE-loaded albumin NP as
compared to mice treated with free molecule of PIC/CAPE;
colon tissues of mice exposed to 2.5% DSS show higher ex-
pression of both HIF-1α and p65 (Fig. 7a, c).
Furthermore, level of p65 and HIF-1α in colonic tissue ly-
sate was assessed using ELISA assay (Supplementary Fig. 1). It
was observed that PIC/CAPE-loaded albumin NP significantly
(p < 0.001) decreased the expression of p65 and HIF-1α as
compared to free molecules of PIC/CAPE (Fig. 7b, d).
Fig. 5 Effect of PIC and CAPE-
loaded albumin NP treatment on
colon histology and inflammation
score. Improved colon
histological outcome in mice
treated with PIC and CAPE-
loaded albumin NP + DSS (a).
The cryptic structure in the
epithelial layer of healthy PIC and
CAPE-loaded albumin NP group
is identical (a). However,
infiltration of cytokines and the
distorted epithelial layer can be
observed in the free PIC and
CAPE-treated mice (a).
Significant (p < 0.0001) low
inflammation was recorded in
PIC/CAPE-loaded albumin NP-
treated group is reported as
compared to free PIC/CAPE
groups (b). N = 5–6 mice per
group. *p < 0.05, **p < 0.01 and
***p < 0.001.ΔΔΔp < 0.001
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Discussions
Therapeutic activity of PIC and CAPE against several disor-
ders is supported by the presence of their phenolic nature [52].
However, it has been documented that phenolic compounds
are poorly soluble in aqueous media which limit their efficacy
[53]. Hence, we have formulated PIC and CAPE as albumin
nanoparticles to overcome solubility and bioavailability is-
sues. Our previous work indicates that CAPE was protective
in experimental colitis via reduction in levels of pro-
inflammatory mediators and enhancement of epithelial barrier
function [23]. Our current work indicates that enhanced ther-
apeutic outcome can be achieved at a lower dose when CAPE
and PIC is delivered as albumin nanoparticles.
In the present study, we have tested albumin-loaded nano-
particles containing PIC and CAPE for the first time in a DDS-
induced murine model of colitis. Effect of drug amount of PIC
and CAPE on particle size, polydispersity index, zeta potential
and entrapment efficiency were studied. It was found that
increase in drug concentration leads to increase in particle
size, polydispersity index and zeta potential (Figs. 1 and 2).
However, entrapment efficiency decreases due to increase in
drug amount. Thus, after careful optimisation, we selected 20-
mg drug concentration to formulate albumin NP loaded with
PIC and CAPE for evaluation of the anti-inflammatory poten-
tial of PIC and CAPE in chemically induced mouse model of
colitis. Parameters such as DAI, rectal bleeding, shortening of
colon length, weight of colon and alteration of epithelial layer
of colon in DSS induce colitis were also accessed during eval-
uation of anti-inflammatory activity in vivo [54–56]. Early
signs of colon inflammation such as weight loss and increase
DAI score were reported in DSS alone group as shown in
Fig. 6 Effect of free PIC/CAPE and PIC/CAPE-loaded albumin NP on
expression of pro-inflammatory mediators. The colon tissue homogenates
analysed for MPO (a), INF-ϒ (b), IL-6 (c) and TNF-α (d). It was noted
that PIC/CAPE-loaded albumin decreases the expression of inflammatory
markers when compared with free PIC/CAPE. *p < 0.05, p < 0.01 and
***p < 0.001 compared with the healthy group. ΔΔp < 0.01 and
ΔΔΔp < 0.001 compared with the same dose of free PIC/CAPE
molecules. N = 5–6 mice per group
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Fig. 3, this indicates that the presence of DSS in drinking
water induces colitis in mice. However, these symptoms were
absent in PIC and CAPE-loaded albumin NP. Free PIC and
CAPE-treated mice showed some degree of attenuations these
symptoms during active colitis (Fig. 3). These findings indi-
cate that PIC and CAPE can exert anti-inflammatory effect
during active colitis which is potentiated when these com-
pounds are formulated as albumin nanoparticles.
After dissection of the mice and isolation of the colon
gross morphology was observed appreance of blood clots,
loose stool and shortening of colon was reported in DSS
alone, free PIC and CAPE-treated group (Fig. 4a). PIC
and CAPE-loaded albumin NP-treated mice exhibit nor-
mal stool, no blood and the equivalent colon length com-
pared with the healthy group as depicted in Fig. 4a.
Furthermore, no significant difference in colon length
PIC/CAPE albumin NP-treated groups was observed
when compared healthy group (Fig. 4b). The entire colon
weight was recorded, colons from of PIC and CAPE-
loaded albumin NP-treated mice illustrate no significant
difference in weight as compared with healthy groups, a
small degree of loss in colon weight was reported in free
PIC and CAPE-treated mice (Fig. 4c). These findings in-
dicate that administration of PIC and CAPE as albumin
Fig. 7 Effect of PIC and CAPE-loaded albumin NP on transcription
proteins p65 and HIF-1α in colon. Lower levels of p65 in PIC and
CAPE-loaded albumin NP + DSS-treated group is observed by
immuno-histochemistry (a) and ELISA assay (b). Similarly, expression
of HIF-1α decreases significantly in PIC and CAPE-loaded albumin NP-
treated mouse colon when assessed by immuno-histochemistry (c) and
ELISA assay (d). Values are mean ± SEM. *p < 0.05, p < 0.01 and
***p < 0.001 compared with the healthy group. ΔΔΔp < 0.001
compared with the same dose of free PIC/CAPE molecules. N = 5–6
mice per group
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nanoparticles is highly effective in protecting the gross
morphology of the colon during active colitis.
Treatment with PIC and CAPE-loaded albumin NP result-
ed in marked improvement in colon histology (Fig. 5a), to-
gether with improved blinded inflammation scores (Fig. 5b).
In murine model of DSS-induced colitis, the increase in MPO
and pro-inflammatory cytokines occurred after the onset of
colon inflammation due to physical barrier disruption. PIC
and CAPE-loaded albumin NP-treated mice show no increase
in MPO (Fig. 6a) and only small increase in other pro-
inflammatory cytokines (Fig. 6b–d).
Several previous findings indicate inflammation results in
overstimulation of transcription protein such as p65 and HIF-
1α in ulcerative colitis and colorectal cancer which results in
damage of epithelial layer of colon [57, 58]. Overactivation of
nuclear factor p65 and HIF-1α has also been reported in UC
patients [59, 60]. Colon tissue from mice treated with DSS
alone showed upregulation of both nuclear factor p65 and
HIF-1α during active inflammation as compared with healthy
mice (Fig. 7a–d). Treatment with free CAPE and PIC results
in small reduction of p65 and HIF-1α; this effect is signifi-
cantly enhanced when CAPE and PIC is administered as al-
bumin nanoparticles (Fig. 7a–d). Hence, we can conclude that
the therapeutic anti-inflammatory potential of CAPE and PIC
to modulate the hypoxia inducible factor and nuclear factor-
kappa beta pathways can be improved by using an inflamma-
tion targeting drug delivery system (Supplementary Figure 1).
Thus nanotechnology could play an important role in improv-
ing therapeutic potential of natural compounds such as CAPE
and PIC resulting in the development of a novel therapeutic
option for inflammatory bowel diseases.
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